Entrada Therapeutics, Inc.

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to reach intracellular targets that have historically been difficult to access. Its pipeline is focused on neuromuscular and inherited retinal diseases, with lead programs in Duchenne muscular dystrophy and a partnered myotonic dystrophy program with Vertex.

−605,0 %

−565,5 %

−87,9 %

12.53

12.53

— Entrada Therapeutics, Inc.
%
Clinical-stage DMD programs0% Lead exon-skipping and genetic medicine candidates for Duchenne muscular dystrophy.
Partnered neuromuscular program100% VX-670 collaboration with Vertex for myotonic dystrophy type 1.
Platform technology0% Endosomal Escape Vehicle platform used to deliver therapeutics into cells.
Preclinical discovery pipeline0% Earlier-stage programs in neuromuscular and inherited retinal diseases.

Entrada does not yet sell approved products; its current economic counterparties are collaboration partners,...

  • Strategic collaboration partnerprimary

    Vertex funds and co-develops VX-670, providing non-product revenue and development support.

  • Clinical trial patientsprimary

    Patients with DMD and DM1 who enroll in studies and generate clinical data needed for approval.

  • Physicians and specialty centerssecondary

    Neuromuscular specialists and treatment centers that would diagnose, prescribe, and monitor therapy.

  • Third-party payorssecondary

    Insurers and public payors that would determine access and reimbursement for any approved medicines.

Entrada is headquartered in the United States, but its clinical development footprint spans the U.S., the U.K...

  • •Headquartered in the United States
  • •Clinical programs run in the U.S., U.K., and European Union
  • •EU filing planned for ENTR-601-50
  • •DMD patient pool cited across the U.S. and Europe
  • •Future commercialization would likely be multinational if approved

Entrada's strategy is to validate its EEV platform through clinical readouts in DMD and through the Vertex-partnered...

01
Clinical advancement of lead DMD programsshort-term

Human data is the main value driver for a clinical-stage biotech and de-risks the platform.

02
Platform validation through shared EEV biologymedium-term

Success in one candidate can support the broader pipeline and improve partnering leverage.

03
Partnership execution with Vertexshort-term

Collaboration revenue and external validation reduce funding pressure and broaden development reach.

Entrada is exposed to the binary risk profile of clinical-stage drug development: programs can fail on safety,...

critical

Clinical development failure

The company has no approved products and relies on a small number of programs to prove efficacy and safety.

Scope
ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51, VX-670
Materiality
high
high

Regulatory and approval delays

Rare-disease programs require multiple agency interactions and can be slowed by additional data requests.

Scope
FDA, EMA, EU filing and future marketing approvals
Materiality
high
high

Manufacturing scale-up and supply risk

EEV-based therapeutics have not been manufactured at commercial scale and may be difficult to scale reliably.

Scope
Clinical and future commercial supply
Materiality
high
high

Financing risk

The company expects operating losses and negative cash flow until product sales, if ever, begin.

Scope
Need for equity, debt, or collaboration funding
Materiality
high
medium

Partner concentration

A substantial portion of revenue to date has come from the Vertex agreement.

Scope
Collaboration revenue and development support
Materiality
medium
ASC 606 collaboration revenue
Can shift revenue between periods without changing underlying cash generation
Research and development expense estimation
Affects operating loss and comparability across quarters
Stock-based compensation
Impacts operating expenses and non-cash dilution analysis
Tax capitalization of R&D under Section 174
Affects tax expense and deferred tax timing

Entera Bio Ltd.

ENTX · Biological Products, (No Diagnostic Substances)

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

ENDRA Life Sciences Inc.

NDRA · Electromedical & Electrotherapeutic Apparatus

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

Lyra Therapeutics, Inc.

LYRA · Surgical & Medical Instruments & Apparatus

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

: 28.4.2026